StockLens

Divi's Laboratories Limited (DIVISLAB) share price and analysis

DIVISLAB last traded at ₹11,150.00 (+0.63%) on the NSE. Market cap ₹2,95,997 Cr (Large cap), Pharma & Healthcare sector.

Overall rating: 8.0/10 (Excellent)

Long-term view: Strong long-term candidate. Business quality and valuation clearly outweigh the weaknesses. Trade bias (next few weeks): Strong long. Trend and momentum are clearly pointing up.

Strengths of DIVISLAB

Weaknesses of DIVISLAB

Key numbers

NumberValueAssessmentNormal range
P/E (TTM)88.0Expensive vs peers37.0–49.3 (sector median 41.1)
Forward P/E63.1Profits expected to growbelow today's P/E (88.0) and near 41
Price / book16.43High6–12 (high ROE allows more)
EPS (TTM)₹126.73Profitableabove ₹0
Return on equity20.1%Strong15%+ (below 10% is weak)
Debt / equity0.00Low debtbelow 1.0 (under 0.5 is great)
Net margin27.6%Healthy10%+ (below 5% is thin)
Operating margin34.0%Strong20%+ strong, below 10% thin
Revenue growth+35.4%Growing well10%+ a year (below 3% is weak)
Profit growth+63.6%Growing well10%+ a year (falling is weak)
Dividend yield0.27%Small payout1.5%+ (none is fine for growth firms)
Current ratio4.59Comfortable1.5+ (below 1 is tight)
52W high₹11,824.006% below · near the highprice in the top 40% of its 52-week range
52W low₹5,647.50Price is 97% above it
50-DMA₹9,663.20Price 15.4% aboveprice above it = short-term uptrend
200-DMA₹7,559.33Price 47.5% aboveprice above it = long-term uptrend
1Y return+66.6%Beat the Nifty 50Nifty 50 did −0.4%
Beta0.18Steadier than the market0.8–1.3 (1 = moves with market)
Promoter / insider52.0%Owners have a big stake50%+ shows owner commitment
Institutions29.9%Moderate interest30%+ is strong
Analyst target₹11,083.110.6% downside · 28 analysts8%+ upside

Questions about DIVISLAB

What is the share price of Divi's Laboratories Limited (DIVISLAB) today?

DIVISLAB last traded at ₹11,150.00 (+0.63% on the day) on the NSE. Its 52-week range is ₹5,647.50 to ₹11,824.00. Prices are delayed and come from Yahoo Finance.

Is DIVISLAB a good stock for the long term?

StockLens rates DIVISLAB 8.0 out of 10 (Excellent) overall. Its long-term verdict is "Strong long-term candidate": Business quality and valuation clearly outweigh the weaknesses. Strengths: high ROE, low debt, uptrend. Concerns: expensive vs peers, cash burn.

Is DIVISLAB share overvalued?

DIVISLAB trades at a P/E of 88.0 against a Pharma & Healthcare median of 41.1, which StockLens rates as "Expensive vs peers". Its price-to-book ratio is 16.43.

Is DIVISLAB good for short-term trading?

The trade bias for the next few weeks is "Strong long": Trend and momentum are clearly pointing up. The price is 47.5% above its 200-day average and 14-day RSI is 69.

Which stocks are similar to DIVISLAB?

Similar Pharma & Healthcare stocks of comparable size include Sun Pharmaceutical, Torrent Pharmaceuticals, Laurus Labs, Apollo Hospitals, Zydus Lifesciences. You can compare up to 4 of them side by side on StockLens.

About Divi's Laboratories Limited

Divi's Laboratories Limited engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceuticals in India, North America, Asia, Europe, and internationally. The company also undertakes custom synthesis contract manufacturing services of APIs and intermediates; and supplies a range of carotenoids, such as astaxanthin, beta-carotene, lycopene, canthaxanthin, apocarotenal, and vitamins used in the food, beverage, dietary supplement, pet food, and feed industries. It also exports its products. The company was formerly known as Divi's Research Center and changed its name to Divi's Laboratories Limited in 1994. Divi's Laboratories Limited was incorporated in 1990 and is based in Hyderabad, India.

Stocks similar to DIVISLAB

Compare DIVISLAB with SUNPHARMA, TORNTPHARM, LAURUSLABS

Educational information, not investment advice. Data from Yahoo Finance and NSE Indices; prices may be delayed.